1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19. N Engl J Med. 2020;383(19):1813-1826 .
Google Scholar | Crossref2. NIH COVID-19 Treatment Guidelines, 2021.
Google Scholar3. VEKLURY (remdesivir) for injection [package insert] . 2020. Foster City, CA. Gilead Sciences, Inc.
Google Scholar4. Szente, L, Puskas, I, Sohajda, T, et al. Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations. Carbohydr Polym. 2021 July 15;264:118011.
Google Scholar | Crossref | Medline5. Abel, S, Allan, R, Gandelman, K, Tomaszewski, K, Webb, DJ, Wood, ND. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig. 2008;28(7):409‐420.
Google Scholar | Crossref | Medline6. Luke, DR, Tomaszewski, K, Damle, B, Schlamm, HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291‐3301.
Google Scholar | Crossref | Medline7. Adamsick, ML, Gandhi, RG, Bidell, MR, et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020;31(7):1384‐1386.
Google Scholar | Crossref | Medline8. Luke, DR, Wood, ND, Tomaszewski, KE, Damle, B. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) in subjects on hemodialysis. Nephrol Dial Transplant. 2012;27(3):1207‐1212.
Google Scholar | Crossref | Medline9. Kiser, TH, Fish, DN, Aquilante, CL, et al. Evaluation of sulfobutylether-beta-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015;19(1):32.
Google Scholar | Crossref10. Thakare, S, Gandhi, C, Modi, T, et al. Safety of remdesivir in patients With acute kidney injury or CKD. Kidney Int Rep. 2021;6(1):206‐210.
Google Scholar | Crossref | Medline11. Estiverne, C, Strohbehn, IA, Mithani, Z, et al. Remdesivir in patients With estimated GFR <30 ml/min per 1.73 m(2) or on renal replacement therapy. Kidney Int Rep. 2021;6(3):835‐838.
Google Scholar | Crossref | Medline12. Ackley, TW, McManus, D, Topal, JE, Cicali, B, Shah, S. Correction for ackley, et al., “A valid warning or clinical lore: an evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. Antimicrob Agents Chemother. 2021;65(7):e0094321.
Google Scholar | Crossref | Medline13. Aiswarya, D, Arumugam, V, Dineshkumar, T, et al. Use of remdesivir in patients With COVID-19 on hemodialysis: a study of safety and tolerance. Kidney International Reports. 2021;6(3):586‐593.
Google Scholar | Crossref | Medline